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The strong relationship between cigarette smoking and cardiovascular disease (CVD)
has been well-documented, but the mechanisms by which smoking increases CVD
risk appear to be multifactorial and incompletely understood. Mesenchymal stem cells
(MSCs) are regarded as an important candidate for cell-based therapy in CVD. We
hypothesized that MSCs derived from induced pluripotent stem cell (iPSC-MSCs) or
bone marrow (BM-MSCs) might alleviate cigarette smoke (CS)-induced cardiac injury.
This study aimed to investigate the effects of BM-MSCs or iPSC-MSCs on CS-induced
changes in serum and cardiac lipid profiles, oxidative stress and inflammation as
well as cardiac function in a rat model of passive smoking. Male Sprague-Dawley
rats were randomly selected for exposure to either sham air (SA) as control or 4%
CS for 1 h per day for 56 days. On day 29 and 43, human adult BM-MSCs,
iPSC-MSCs or PBS were administered intravenously to CS-exposed rats. Results
from echocardiography, serum and cardiac lipid profiles, cardiac antioxidant capacity,
cardiac pro- and anti-inflammatory cytokines and cardiac morphological changes were
evaluated at the end of treatment. iPSC-MSC-treated group showed a greater effect
in the improvement of CS-induced cardiac dysfunction over BM-MSCs-treated group
as shown by increased percentage left ventricular ejection fraction and percentage
fractional shortening, in line with the greater reversal of cardiac lipid abnormality.
In addition, iPSC-MSCs administration attenuated CS-induced elevation of cardiac
pro-inflammatory cytokines as well as restoration of anti-inflammatory cytokines and
anti-oxidative markers, leading to ameliorate cardiac morphological abnormalities.
These data suggest that iPSC-MSCs on one hand may restore CS-induced cardiac
lipid abnormality and on the other hand may attenuate cardiac oxidative stress and
inflammation via inhibition of CS-induced NF-κB activation, leading to improvement of
cardiac remodeling and dysfunction. Thus, iPSC-MSCs may be a promising candidate
in cell-based therapy to prevent cardiac complications in smokers.
Keywords: cigarette smoke, induced pluripotent stem cells, inflammation, lipids metabolism, mesenchymal stem
cells, oxidative stress
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INTRODUCTION
Cigarette smoking, one of the major risk factors for the
development of cardiovascular disease (CVD), accounts for
morbidity and mortality of cardiac events, including coronary
heart disease, atherosclerosis, myocardial infarction and stroke
(Burns, 2003). The association between CVD and the effect
of passive (secondhand) smoking needs to be taken into
consideration, as passive smoking increases the risk of coronary
heart disease, myocardial infarction, stroke and cardiac death
(Barnoya and Glantz, 2005; Minicucci et al., 2009). Despite
evidence linking cigarette smoke (CS) exposure with CVD,
the precise mechanism of CS-induced CVD remains largely
unknown. The development of a rodent passive smoking model
to study the early changes in CS-induced cardiac dysfunction
would greatly help to delineate the pathophysiology of CVD.
CS exerts its deleterious cardiovascular effects through several
potential mechanisms involving oxidative stress, inflammation
and modification of lipid profiles, leading to initiation and
progression of atherothrombosis (Ambrose and Barua, 2004;
Salahuddin et al., 2012). There is increasing evidence that
smoking contributes to cardiac disorders is associated with lipid
abnormality. CS exerts detrimental effect on the lipid metabolism,
with elevation of serum cholesterol, triglycerides, and very low-
density lipoprotein (VLDL)-cholesterol, along with reduction
of serum high-density lipoprotein (HDL)-cholesterol and Apo
lipoprotein A-I (Apo A-I) in smokers compared to non-smokers
(Craig et al., 1989). Besides, elevation of plasma free fatty acids
(FFA) levels was found in smokers compared to non-smokers
(Hellerstein et al., 1994; Neese et al., 1994). Fatty acids are
utilized by the heart to generate a constant supply of ATP needed
for normal myocardial function (Stanley et al., 2005). Cardiac
lipid profile also affects electrophysiological and mechanical
function due to modulation of the physicochemical properties
of cellular membranes (van der Vusse et al., 2000). However,
the physiological and biochemical responses to CS have not
been fully characterized in terms of cardiac lipid profile and
function.
Nowadays, there is an increasing interest in the therapeutic
potential of mesenchymal stem cells (MSCs) in CVD. MSCs
rescued damaged hearts by reducing the scar size in clinical
trials, ameliorated cardiac injury and improved ventricular
function in animal models of acute and chronic myocardial
infarction, as well as non-ischemia dilated cardiomyopathy
(Gnecchi et al., 2012). In this study, a novel cell type of
MSCs which derived from induced pluripotent stem cells
(known as iPSC-MSCs) and bone marrow-derived MSCs (BM-
MSCs) was intravenously administered to the CS-exposed
rat model for comparison of their efficacies. BM-MSCs
have limited capacity for proliferation and differentiation
while iPSC-MSCs have unlimited resource, no need for
immunosuppression, more consistency and high proliferative
ability (expanded up to 40 passages) without loss of self-
renewal capacity and constitutively express surface antigens
of multipotent MSCs (Lian et al., 2010). Due to a lack
of information available regarding the therapeutic potential
of systemic delivery of iPSC-MSCs on CS-induced cardiac
dysfunction, this study was aimed to explore the regulation of
cardiac lipid metabolism after CS exposure and to compare the
therapeutic potential of iPSC-MSCs over BM-MSCs on various
outcomes including cardiac function, cardiac lipid profile,




Male Sprague-Dawley rats were purchased from and kept in
the Laboratory Animal Unit of the University of Hong Kong,
which is fully accredited by the Association for Assessment
and Accreditation for Laboratory Animal Care (AAALAC
International). All the animal experiments were performed in
strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes
of Health. All experimental procedures were approved by the
Committee on the Use of Live Animal in Teaching and Research
(CULATR, No.:2377-11) of the University of Hong Kong. The
animals were kept at 22 ± 1◦C, humidity (65∼75%) and
day/night cycle (12/12-h light/dark).
Preparation of iPSC-MSCs and
BM-MSCs
Human iPSC-MSCs were prepared based on a previously
described protocol (Lian et al., 2010). Characterized adult human
BM-MSCs were purchased commercially (catalog No.: PT-2501,
Cambrex Bioscience, Rockland, ME, United States). MSCs were
cultured with DMEM plus 10% fetal calf serum (GIBCO,
Carlsbad, CA, United States), basic fibroblast growth factor
(bFGF, 5 ng/mL), and epidermal growth factor (EGF, 10 ng/mL).
Details can be found in Supplementary Materials.
CS-Exposed Rat Model
The passive smoking exposure used in this study was adapted
from the original design as previously reported (Chan et al.,
2009; Li et al., 2014). Briefly, rats (at 6 weeks of age, 160–200 g)
were exposed to 4% CS, which produced comparable cotinine
concentration to intermediate smokers (i.e., consumption of
11–20 cigarettes per day) for 1 h daily using commercially
available cigarette [11 mg tar, 0.8 mg nicotine; (Camel; filter, R.J.
Reynolds, Winston-Salem, NC, United States)] for 56 days in
the ventilated chambers. All filters from cigarettes were removed
before lighting up. The control rats underwent same procedure of
exposure with fresh air.
Groups and Treatment
Rats were divided into four groups, including sham air
group (SA), CS group (CS), BM-MSCs treatment plus CS
(BM-MSCs/CS) group and iPSC-MSCs treatment plus CS
(iPSC-MSCs/CS) group, respectively. During the exposure
period, two doses of BM-MSCs or iPSC-MSCs (3 × 106 cells
in 0.5 ml) were injected intravenously (i.v.) via tail vein to
the BM-MSCs/CS or iPSC-MSCs/CS group on day 29 and day
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TABLE 1 | Echocardiographic study.
BM- iPSC-
SA CS MSCs/CS MSCs/CS
LVEDD (mm) 7.95 ± 0.32 8.40 ± 0.23 8.04 ± 0.25 8.45 ± 0.24
LVESD (mm) 4.57 ± 0.43 5.61 ± 0.16∗ 5.53 ± 0.24 5.16 ± 0.17
LVPWd (mm) 1.90 ± 0.11 1.79 ± 0.10 1.85 ± 0.06 1.89 ± 0.06
LVPWs (mm) 2.96 ± 0.15 2.47 ± 0.07∗ 2.63 ± 0.16 2.74 ± 0.08
LVEF (%) 78.33 ± 3.27 67.14 ± 1.75∗∗ 68.43 ± 1.97 74.57 ± 0.97#
FS (%) 43.17 ± 3.61 33.29 ± 1.15∗∗ 34.43 ± 1.49 39.00 ± 0.81#
LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic
dimension; LVPWd, left ventricular end diastolic posterior wall dimension; LVPWs,
left ventricular end systolic posterior wall dimension; LVEF, left ventricular ejection
fraction; FS, fractional shortening. Results are expressed as mean ± SEM; SA,
n = 6; CS, n = 7; BM-MSCs/CS, n = 7; iPSC-MSCs/CS, n = 7. Data were
analyzed by one-way ANOVA. ∗P < 0.05, ∗∗P < 0.01 or comparison between
the CS group and SA group. #P < 0.05 for comparison between iPSC-MSCs/CS
or BM-MSCs/CS group and CS group.
43, while other groups (SA and CS groups) were injected with
phosphate-buffered saline (PBS) of the same volume. All rats
were underwent echocardiography and sacrificed 24 h after the
last CS exposure (Supplementary Figure S1).
Echocardiographic Analysis
Echocardiography was conducted on all rats in the supine
position under anesthesia with ketamine (70 mg/kg body
weight)/xylazine (6 mg/kg body weight) (i.p.) by using a high
resolution Micro-Ultrasound System (VevoTM 770, Visual
Sonics Inc., Toronto, ON, Canada) equipped with a 25-MHz
linear transducer before termination of the experiment.
Bi-dimensional echocardiographic variables were measured
from M-mode images, including left ventricular end diastolic
dimension (LVEDD), left ventricular end systolic dimension
(LVESD), left ventricular end diastolic posterior wall dimension
(LVPWd) and left ventricular end systolic posterior wall
dimension (LVPWs). Left ventricular systolic function was
accessed by calculating percentage left ventricular ejection
fraction (%LVEF) and percentage fractional shortening
(%FS). After the echocardiographic measurement, rats were
euthanized with pentobarbital at a lethal dose (100 mg/kg body
weight). Blood and heart tissues were collected for further
study.
Preparation of Total Protein and
Nuclear/Cytoplasmic Protein Fraction
Frozen heart tissue (without the atria) was ground up with
a mortar and pestle under liquid nitrogen. For total protein
extraction, heart tissue was homogenized in T-PER R© tissue
protein extraction reagent containing protease/phosphatase
inhibitors cocktail (Thermo Scientific, Rockford, IL, United
States) and 100 mM Phenylmethanesulfonyl fluoride (PMSF)
following the manufacturer’s instruction. The extraction of
nuclear/cytoplasmic protein was performed using NE-PER R©
nuclear and cytoplasmic extraction reagents (Thermo Scientific,
Rockford, IL, United States) according to manufacturer’s
instruction. Protein concentrations were measured by
Bradford protein assay (Bio-Rad Laboratories, Philadelphia,
PA, United States) using bovine serum albumin (BSA) as
standards.
Lipid Extraction and Measurement
Lipid extraction from the frozen heart tissue was adapted and
carried out according to the established protocol (Zou, 2011).
Briefly, heart tissues were weighted (about 20 mg) and put
into a 15 ml tube, 4 ml lipid extraction buffer (2 volume
chloroform and 1 volume methanol) was added into the tube.
After vigorously vortex, the tissue was incubated for 16 h
at 4◦C. Two milliliters 0.6% sodium chloride was added and
the mixture was centrifuged at 2,000 × g for 20 min. The
organic layer (lower layer) of the liquid was collected and
was evaporated the organic solvent by using SavantTM SC110A
Speed Vac Plus concentrator with Universal Vacuum System
Plus (Thermo Scientific). The pellet was dissolved with lipid
dissolution buffer (5 volume isopropanol, 2 volume water and
2 volumes of Triton X-100) for the measurement of lipid
parameters. Levels of cholesterol and triglyceride in the serum
and heart lipid extract were determined with kits from Stanbio
Laboratory (Cat #1010 and 2100; Boerne, TX, United States)
according to manufacturer’s instructions. Serum and cardiac
FFA levels were determined with half-micro test kit from Roche
(Cat #11-383-175-001, Roche Applied Science, Mannheim,
Germany). Levels of lipid parameters in heart homogenate were
corrected by the wet weight of heart tissue used in the lipid
extraction.
TABLE 2 | Effects of MSCs on serum and cardiac lipid profiles.
SA CS BM-MSCs/CS iPSC-MSCs/CS
Serum lipid profile
Cholesterol (mg/dL) 60.98 ± 3.78 66.86 ± 2.66 62.20 ± 1.84 59.50 ± 1.64
Triglycerides (mg/dL) 138.7 ± 12.4 155.0 ± 15.8 146.2 ± 28.5 146.8 ± 11.3
FFA (µM) 74.03 ± 6.02 111.0 ± 22.5 120.7 ± 17.9 117.3 ± 18.73
Cardiac lipid profile
Cholesterol (mg/g tissue) 2.338 ± 0.10 2.726 ± 0.10∗ 2.406 ± 0.11 2.317 ± 0.10#
Triglycerides (mg/g tissue) 4.842 ± 0.13 6.517 ± 0.54∗∗ 4.986 ± 0.27# 5.119 ± 0.22#
FFA (µ mole/g tissue) 1.727 ± 0.14 1.160 ± 0.08∗∗ 1.241 ± 0.09 1.550 ± 0.12#
Data are expressed as mean ± SEM; n = 6–8 in each group. Data were analyzed by one-way ANOVA. ∗P < 0.05, ∗∗P < 0.01 or comparison between the CS and SA
groups. #P < 0.05 for comparison between the iPSC-MSCs/CS or BM-MSCs/CS groups and CS group. FFA, free fatty acid.
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FIGURE 1 | Effect of MSCs on cardiac expressions of proteins regulating cholesterol, triglycerides and FFA metabolism. (A) CS exposure caused significant elevation
of cardiac expression of LDL-R, which was attenuated in both the BM-MSCs/CS and iPSC-MSCs/CS groups. (B) CS led to increased cardiac expression of
HMGCR, which was attenuated in the iPSC-MSCs/CS group. (C) CS reduced cardiac expression of ABCA1, which was restored in the iPSC-MSCs/CS group.
(D) CS exposure significantly reduced protein expression of LPL, which was restored in the iPSC-MSCs/CS group. (E) CS exposure led to a significant reduction in
protein expression of cardiac CD36, which was significantly restored in the iPSC-MSCs/CS group. (F) Cardiac FAS protein expression was inhibited after CS
exposure, which showed a trend of restoration but not reaching significant level in both the BM-MSCs/CS and iPSC-MSCs/CS groups. Cardiac levels of protein
expression were normalized to GAPDH levels and expressed as fold change vs. relative control. Data are expressed as mean ± SEM; n = 7–8. Data were analyzed
by one-way ANOVA. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 for comparison between the CS and SA groups. #p < 0.05, ##p < 0.01 for comparison between the
BM-MSCs/CS or iPSC-MSCs/CS groups and CS group, respectively. LDL-R, low density lipoprotein receptor; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; ABCA1, ATP-binding cassette protein-A1; LPL, Lipoprotein lipase; CD36, fatty acid
translocase (FAT)/CD36; FAS, fatty acid synthase.
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FIGURE 2 | Effect of MSCs on cardiac levels of oxidative stress markers. Cardiac T-AOC (A), SOD activity (B) and CAT activity (C) were reduced after CS exposure,
which were significantly restored in the iPSC-MSCs/CS group. Data are expressed as mean ± SEM; n = 7–8. Data were analyzed by one-way ANOVA. ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001 for comparison between the CS and SA groups. #p < 0.05, ##p < 0.01 for comparison between the BM-MSCs/CS or iPSC-MSCs/CS
group and the CS group, respectively. T-AOC, total anti-oxidant capacity; SOD, superoxide dismutase; CAT, catalase.
Determination of Oxidative Stress and
Pro-/Anti-inflammatory Markers
Total anti-oxidant capacity (T-AOC) and enzyme activity of total
superoxide dismutase (SOD) were examined by kits (Nanjing
Jiancheng Bioengineering Institute, China) and activity of
catalase (CAT) was determined by Amplex R© Red catalase assay kit
(Molecular Probes Inc., Invitrogen, Eugene, OR, United States).
Commercial Enzyme-linked immunosorbent assay (ELISA) kits
were used to measure the levels of cytokine-induced neutrophil
chemoattractant-1 (CINC-1, resembles to human IL-8; R&D
Inc., Minneapolis, MN, United States), TNF-α (eBioscience,
San Diego, CA, United States), IL-10 (BD Biosciences, San
Diego, CA, United States), and adiponectin (Invitrogen, Eugene,
OR, United States) in rat heart homogenates according to the
manufacturer’s instructions. The absorbance was measured by a
microplate-reader and the results were corrected by heart protein
concentration.
Western Blot Analysis
Equal amounts of heart protein extractions (40 µg) were
separated in 10% SDS–PAGE gel and transferred onto a
nitrocellulose membrane (0.45 µm, Amersham Hybond ECL,
GE Healthcare, Germany). After blocking, membranes were
incubated with diluted specified primary antibodies, including
NF-κB p65, IκBα (1:1000, catalog No.: #4764 and #4814, Cell
Signaling), ATP-binding cassette protein-A1 (ABCA1) (1:1000,
catalog No.: NB400-105, Novus Biologicals, Littleton, CO,
United States), fatty acid translocase (FAT)/CD36 (CD36), fatty
acid synthase (FAS), 3-hydroxy-3-methylglutaryl coenzyme
A reductase (HMGCR) or low density lipoprotein receptor
(LDL-R) (1:500, catalog No.: NB110-59724, NB400-114,
NBP1-50713 and NB110-57162, Novus Biologicals), lipoprotein
lipase (LPL) (1:200, catalog No.: sc-373759, Santa Cruz
Biotechnology, Inc., Dallas, TX, United States) at 4◦C overnight.
Before developing with an enhanced chemiluminescence
(ECL) reagent (Amersham, Piscataway, United Kingdom),
membranes were incubated with the appropriate horseradish
peroxidase (HRP)-conjugated secondary antibodies (Dako,
Denmark). Bands were visualized on medical X-ray film
(Fumingwei, Shenzhen, China). After stripping, membranes
were re-probed for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) or Lamin A/C as loading control. Densitometric
analysis of the bands was performed with Gene Tools
(Syngene), and results were expressed as fold change to
relative control.
Histology
Hematoxylin and eosin (H&E) for morphological changes
and Sirius red staining for fibrotic detection were performed
on formalin-fixed paraffin-embedded heart sections (5 µm).
Transverse sections were captured digitally, and acquired by
using a Zeiss Axioskop 2 plus microscope (Zeiss, Göttingen,
Germany). Cardiomyocyte cross-sectional area was measured
using the Axio Vision Rel. 4.6 software (Zeiss). We traced the
outline of at least 100 cardiomyocytes per heart, and the data
were averaged. Quantification of the Sirius red staining was
determined as positive area in any five fields per heart section
and analysis was performed with the help of Image J (NIH)
with additional threshold color plug-ins to process the tiff file
images. Images were analyzed by two independent and blinded
investigators.
Statistical Analysis
All results were expressed as mean ± SEM for indicated number
of animals (n). The comparison among multiple groups was
performed by one-way analysis of variance (ANOVA) followed
by the post hoc Bonferroni’s test. Differences were considered
to be significant when the two-sided p-value was less than
0.05. All statistical analyses were performed using computer





The data from echocardiographic study are presented in
Table 1. The CS-exposed rats (CS group) developed cardiac
contractile dysfunction that was characterized by significantly
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FIGURE 3 | Effect of MSCs on cardiac levels of inflammatory markers. Cardiac levels of pro-inflammatory cytokines CINC-1 (A) and TNF-α (B) were elevated after
CS exposure, which were reserved in both the BM-MSCs/CS and iPSC-MSCs/CS groups. Cardiac levels of anti-inflammatory markers IL-10 (C), adiponectin (D)
were reduced in the CS group, which was reversed in the iPSC-MSCs/CS group. Data are expressed as mean ± SEM; n = 7–8. Data were analyzed by one-way
ANOVA. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 for comparison between the CS and SA groups. #p < 0.05, ##p < 0.01 for comparison between the BM-MSCs/CS
or iPSC-MSCs/CS group and the CS group, respectively. CINC-1, cytokine-induced neutrophil chemoattractant-1; TNF-α, tumor necrosis factor-α; IL-10,
interleukin-10.
decreased %LVEF and %FS when compared with SA-exposed
rats (SA group) (p < 0.01, respectively), which was significantly
restored to a normal status in the presence of iPSC-MSCs
(iPSC-MSCs/CS group; p < 0.05) but not BM-MSCs. There
was also a significant increase of LVESD and a significant
decrease of LVPWs in the CS group compared to the SA
group (p < 0.05, respectively), suggesting a possibility of
morphological changes, which further led to functional
changes observed in CS-induced reduction of %LVEF
and %FS.
iPSC-MSCs Restored Cardiac But Not
Serum Lipid Abnormality
The serum and cardiac lipid profiles are presented in Table 2.
There were no significant differences between groups in serum
cholesterol and triglyceride. Serum FFA level showed a trend of
elevation in the CS group compared to the SA group but not
reaching significant level, which was not reversed in the presence
of either BM-MSCs or iPSC-MSCs.
Cigarette smoke exposure significantly elevated the cardiac
levels of cholesterol and triglyceride (p< 0.05 and p< 0.01,
respectively), which was attenuated after BM-MSCs or
iPSC-MSCs treatment for cardiac triglyceride (p < 0.05,
respectively) while only iPSC-MSCs treatment (iPSC-MSCs/CS
group) significantly reversed cardiac cholesterol (p< 0.05). On
the contrary, CS caused a significant reduction in cardiac FFA





Cigarette smoke exposure caused elevated protein expressions
of LDL-R and HMGCR (p< 0.001 and p< 0.01, respectively),
mediating cholesterol influx and synthesis, and decreased protein
expression of ABCA1 (p< 0.05), controlling the eﬄux of
cholesterol. The reversal of CS-induced up-regulation of LDL-R
protein expression was observed in both the BM-MSCs/CS
and the iPSC-MSCs/CS groups (p< 0.05 and p< 0.01,
respectively). However, the restoration of CS-induced up-
regulation of HMGCR protein expression was found to be
significant only in iPSC-MSCs/CS group (p< 0.01). In addition,
the CS-induced down-regulation of ABCA1 protein expression
was significantly restored only in the iPSC-MSCs/CS group
(p< 0.05) (Figures 1A–C).
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FIGURE 4 | Effect of MSCs on protein expressions of NF-κB signaling pathway in the heart. (A) Protein expression level of cardiac cytoplasmic IκBα was normalized
to GAPDH levels. CS exposure reduced cardiac cytoplasmic IκBα expression level, which was reversed in iPSC-MSCs/CS group. (B) Protein expression level of
cardiac nuclear NF-κB p65 was normalized to Lamin A/C levels. CS exposure increased NF-κB p65 protein expression in the nuclear fraction of the heart, which was
attenuated in both the BM-MSCs/CS and iPSC-MSCs/CS groups. Results are expressed as mean ± SEM; n = 7–8. Data were analyzed by one-way ANOVA.
∗∗p < 0.01, ∗∗∗p < 0.001 for comparison between the CS and SA groups. #p < 0.05, ###p < 0.001 for comparison between the BM-MSCs/CS or iPSC-MSCs/CS




Protein expression of cardiac lipid-metabolizing enzyme LPL was
significantly decreased in CS-exposed group compared to the
SA-exposed group (p < 0.05), which was restored only in the
iPSC-MSCs/CS group (p< 0.05) (Figure 1D).
iPSC-MSCs Regulated Cardiac Fatty
Acid Metabolism-Related Proteins
Cigarette smoke exposure led to a significant reduction in protein
expression of cardiac CD36 and FAS (p< 0.01 and p< 0.05,
respectively). The restoration of CS-induced reduction in cardiac
CD36 protein expression reached significant level only in the
iPSC-MSCs/CS group (p< 0.05) (Figure 1E). However, the
CS-induced suppression of cardiac FAS protein expression was
found to show a trend of reversal but not reaching significance in
both iPSC-MSCs/CS and BM-MSCs/CS groups (Figure 1F).
iPSC-MSCs Attenuated Cardiac
CS-Induced Oxidative Stress
As an overall anti-oxidative marker, cardiac T-AOC was
significantly decreased in CS group (p < 0.01), which was
restored only in the iPSC-MSCs/CS group (p< 0.01) (Figure 2A).
The enzyme activities of cardiac SOD and CAT were significantly
inhibited in the CS group compared to the SA group (p < 0.001
and p < 0.05, respectively), which was significantly restored only




Cardiac levels of pro-inflammatory markers, including CINC-1
and TNF-α, were significantly elevated in the CS group compared
to the SA group (p < 0.05 and p < 0.01, respectively). Both BM-
MSCs/CS and iPSC-MSCs/CS groups attenuated CS-induced
elevations of all these pro-inflammatory mediators (p < 0.01 for
comparison between CS group and BM-MSCs/CS group in the
level of TNF-α, and p < 0.05 for others) (Figures 3A,B). On the
other hand, anti-inflammatory markers, both interleukin-10 (IL-
10) and adiponectin, were significantly reduced in the CS group
compared to the SA group (p< 0.05 and p< 0.001, respectively),
which were significantly reversed only in iPSC-MSCs/CS group
(p< 0.05, respectively) (Figures 3C,D).
iPSC-MSCs Inhibited Cardiac
CS-Induced NF-κB Activation
Due to the major contributing role in oxidative and inflammatory
responses, we further investigated the effects of iPSC-MSCs and
BM-MSCs on the NF-κB signaling pathway, including protein
expression of cardiac cytoplasmic IκBα and nuclear NF-κB
p65. CS exposure caused a significant reduction in the levels
of cardiac cytoplasmic IκBα expression (p < 0.01), indicating
proteasomal degradation as a key step for NF-κB activation, and
a significant elevation of cardiac nuclear NF-κB p65 (p < 0.001),
suggesting nuclear translocation in the CS group compared to
the SA group (Figures 4A,B). iPSC-MSCs treatment significantly
reversed both CS-induced reduction of IκBα (p < 0.05) and
CS-induced upregulation of NF-κB p65 (p < 0.001), but not
BM-MSCs treatment (Figures 4A,B).
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FIGURE 5 | Effect of MSCs on cardiac morphological alterations. (A) Representative photographs show obvious gross differences in transverse ventricular sections
among rats who received different treatments. (B) Representative photomicrographs of cardiomyocytes (magnification, ×400; scale bar = 20 µm).
(C) Representative photomicrographs of myocardial interstitial fibrosis in heart sections stained with Sirius red (magnification, ×200, scale bar = 50 µm).
(D) Quantitative analysis of cardiomyocyte cross-sectional area from at least 100 cardiomyocytes per heart. (E) Quantification of the Sirius red staining was
determined as positive area in five random fields per heart section and analysis was performed using Image J software. Results are expressed as mean ± SEM;
n = 4–6. Data were analyzed by one-way ANOVA. ∗∗p < 0.01, ∗∗∗p < 0.001 for comparison between the CS and SA groups. #p < 0.05 and ###p < 0.05 for
comparison between the BM-MSCs/CS or iPSC-MSCs/CS groups and the CS group, respectively.
iPSC-MSCs Attenuated CS-Induced
Cardiac Hypertrophy and Interstitial
Fibrosis
Extensive cardiac remodeling was observed after 56-day CS
exposure, characterized by elongation of the heart shape
in the gross histological analysis (Figure 5A). Microscopic
observation on heart sections further revealed that the cross
sectional area of cardiomyocytes in the left ventricle was
significantly increased (i.e., hypertrophy) in the CS group
compared to the SA group (p < 0.001). Treatment with either
BM-MSCs or iPSC-MSCs significantly attenuated CS-induced
cardiac hypertrophy in both the BM-MSCs/CS and iPSC-
MSCs/CS groups (p < 0.05 and p < 0.001, respectively)
(Figures 5B,D).
To confirm the presence of the interstitial fibrosis, Sirius red
staining was performed on heart sections (Figure 5C). In line
with the cardiac function, increased cardiac interstitial fibrosis
was observed in the CS group compared to the SA group
(p < 0.01), which was significantly attenuated only in the iPSC-
MSCs/CS group (p< 0.05) (Figure 5E).
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FIGURE 6 | Schematic diagram. Cigarette smoke exposure causes cardiac lipid dysregulation and oxidative stress-induced cardiac inflammation that leads to
morphological alterations (i.e., cardiac remodeling), resulting in cardiac dysfunction. Treatment with iPSC-MSCs counteracts the CS-induced cardiac remodeling and
dysfunction through the restoration of cardiac lipid anomalies and attenuation of cardiac oxidative stress and inflammation via NF-κB signaling pathway. iPSC-MSCs,
induced pluripotent stem cells-derived mesenchymal stem cells. NF-κB, Nuclear factor-kappa B. Solid lines indicate the presented data in this study while dashed
lines indicate the causal relationship that needs further investigation.
DISCUSSION
In this study, we found that the smoking exposure resembling
passive smokers led to contractile dysfunction and cardiac
hypertrophy, and the functional compromise was accompanied
by interstitial fibrosis. iPSC-MSCs were found to be more
effective than BM-MSCs in restoring CS-induced cardiac
dysfunction via regulation of cholesterol, triglyceride and fatty
acid metabolism, attenuation of cardiac inflammation and
oxidative stress as well as amelioration of cardiac remodeling. The
mechanism might partly involve inhibiting the NF-κB signaling
pathway.
The findings of smoking effect on cardiac dysfunction
characterized by lower LVEF and FS was in agreement with a
previous report (Gu et al., 2008). The beneficial effect of MSCs
in improving CS-induced cardiac dysfunction was similar to
previous clinical report with the use of MSCs in patients with
acute myocardial infarction or chronic ischemic cardiomyopathy
(Karantalis and Hare, 2015).
Lipids play important roles in virtually all aspects of biological
life. Cardiac lipid affects electrophysiological and mechanical
function due to modulation of the physicochemical properties of
cellular membranes (van der Vusse et al., 2000). In this study,
the elevation of CS-induced cardiac cholesterol and triglyceride
levels was in line with the previous studies (Latha et al., 1988;
Gokulakrisnan et al., 2011), suggesting that cardiac damage might
be due to the excessive accumulation of cardiac cholesterol and
triglyceride.
Cholesterol plays an essential role in maintaining the structure
of cell membranes; however, excessive cholesterol accumulation
in cells induces cytotoxicity (Tabas, 2002). The cholesterol
homeostasis within the cell is regulated by endogenous synthesis
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mainly by a rate-limiting enzyme HMGCR (Eisa-Beygi et al.,
2014), receptor-mediated endocytosis by LDL-R on the cell
surface and the eﬄux of cholesterol (Tabas, 2002). During
the eﬄux process of excessive cholesterol, ABCA1 initiates
HDL formation (Tang and Oram, 2009) as the primary
gatekeeper in cellular cholesterol removal (Oram and Lawn,
2001; Oram and Vaughan, 2006; Tang and Oram, 2009). CS-
induced elevation in cardiac cholesterol level was due to the
increased cholesterol biosynthesis, increased uptake from blood
stream and the decreased eﬄux of cholesterol through the
elevation of HMGCR and LDL-R, and the reduction of ABCA1
protein expression, respectively. These direct actions of high
cholesterol levels on cardiomyocytes, vascular smooth muscle
cells and endothelium result in cardiac dysfunction by affecting
contractility, excitability and conduction properties (Saini et al.,
2004) and cardiac hypertrophy (Shmeeda et al., 1994), in line
with the current findings. iPSC-MSCs over BM-MSCs treatment
showed a greater capacity in overall reduction in cardiac
cholesterol level through restoration of LDL-R, HMGCR and
ABCA1 expressions, suggesting that the contribution of the
inhibition of synthesis and influx, and the promotion of eﬄux
of cholesterol may restore CS-induced cardiac remodeling and
dysfunction.
Heart is the most energy demanding organ in the body,
which requires constantly high energy supply to sustain the
continuous contractile activity. Most of the cardiac energy
metabolism relies on the oxidation of FA (Stanley et al., 2005).
In general, FA are taken up by the cardiomyocytes from either
plasma FA bound to albumin or from FA contained within
chylomicron or VLDL triacylglycerol via the direct passive
membrane diffusion or carrier-mediated proteins (Lopaschuk
et al., 2010). Among these transporters of FA, FAT/CD36
contributes to 50–60% FA uptake, exerting its key role in the
regulation of cardiac FA metabolism (Lopaschuk et al., 2010).
FAS, an important multi-enzyme protein, mediates fatty acid
synthesis to maintain cardiac function during stress (Razani
et al., 2011). Another functional enzyme LPL which can be
synthesized in cardiomyocytes, is to catalyze the breakdown of
the triglycerides component of lipoproteins and the hydrolysis
of circulating triglyceride-rich lipoproteins to provide FA to
the heart (Augustus et al., 2003). In this study, CS exposure
caused a reduction of cardiac FFA in line with the reduction
of cardiac CD36 expression as the uptake and oxidation of
FA was limited. The CS-induced reduction of cardiac FAS
indicated the reduction of de novo synthesis, in agreement
with a previous study (Razani et al., 2011). The elevation of
cardiac triglyceride level and reduction of cardiac FFA may be
explained by the marked reduction of LPL expression, indicating
the impaired triglycerides clearance. Loss of LPL-derived lipids
leads to decreased triglyceride lipolysis and increased glucose
uptake in heart, resulting in cardiac dysfunction (Augustus et al.,
2003, 2006; Khan et al., 2013). Although neither BM-MSCs
nor iPSC-MSCs treatment could alter the serum FFA level,
treatment with iPSC-MSCs restored cardiac FFA level, in support
of the reversal of cardiac CD36 expression after treatment with
iPSC-MSCs, which accounts for over 50% FA uptake in the
heart.
Oxidative stress, the imbalance between oxidants and
antioxidants, plays an important role in cardiac function (Hori
and Nishida, 2009; Tsutsui et al., 2011). ROS activates a broad
variety of transcription factors such as NF-κB, and eventually
influences cardiac contractile function by oxidizing proteins
involved in excitation-contraction coupling (Tsutsui et al., 2011).
In this study, CS-induced oxidative stress was characterized
by impaired total antioxidant capacity in the heart, which was
restored in the presence of iPSC-MSCs, in agreement with
acute lung injury and stroke models, indicating anti-oxidative
capacity of MSCs (Calio et al., 2014; Shalaby et al., 2014).
CS-induced oxidative stress appears to be at the initial stage
before triggering inflammatory responses due to excessive ROS
production (Das et al., 2012), which would have a great influence
on cardiac function (Frangogiannis, 2012). In line with previous
findings (Guo et al., 2007; Du et al., 2008), CS caused up-
regulation of pro-inflammatory cytokines including CINC-1 (a
homolog to human IL-8) and TNF-α, which was attenuated in
the treatment of either BM-MSCs or iPSC-MSCs. On the other
hand, CS down-regulated anti-inflammatory markers including
IL-10 and adiponectin, which was restored only after iPSC-MSCs
treatment, suggesting the superior capacity of iPSC-MSCs over
BM-MSCs in alleviating inflammation. The anti-inflammatory
cytokine IL-10, one of the major modulator of pro-inflammatory
cytokines/chemokines, prevented TNF-α-induced activation of
NF-κB in cardiomyocytes (Dhingra et al., 2009). Adiponectin, an
adipokine secreted mainly in adipose tissues and cardiomyocytes,
was found to be at low circulating level in CVD (Shibata et al.,
2009). Suppression of TNF-α and induction of IL-10 was found to
be caused by adiponectin (Qi et al., 2014; Watanabe et al., 2014).
In a previous report, cardiac generation of adiponectin had the
protective effect against ischemia/reperfusion injury and against
cardiomyocyte injury in vivo (Wang et al., 2010). In addition,
adiponectin was shown to have an anti-hypertrophic effect in
cardiomyocytes (Shibata et al., 2004).
Cigarette smoke-induced reduction of cardiac cytoplasmic
IκBα levels and upregulation of cardiac nuclear NF-κB p65
levels were in line with previous reports (Gokulakrisnan
et al., 2011; Das et al., 2012), confirming the involvement of
NF-κB activation. Activation of nuclear factor-κB (NF-κB),
a redox-sensitive transcription factor, leads to increased
production of inflammatory cytokines, the key mediators in the
initiation and progression of cardiac damage (Gordon et al.,
2011). In agreement with previous publications (Du et al., 2008;
Wang et al., 2013), we found the restoration of IκBα expression
in the cytoplasm and the reduction in NF-κB p65 expression in
the nuclei after iPSC-MSCs treatment. These results indicated
that iPSC-MSCs treatment could effectively inhibit the activation
of NF-κB and thus attenuate CS-induced oxidative stress
and imbalance of pro-/anti-inflammatory mediators in the
heart.
During cardiac remodeling process, hypertrophy is normally
a compensatory response at the initiation of cardiac damage,
leading to morphological adaptation to preserve the cardiac
function. However, we observed cardiac dysfunction after 8-week
CS exposure, which may be due to prolonged cardiac remodeling,
in agreement with a previous study (Gu et al., 2008). In this
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study, attenuation of CS-induced cardiomyocyte hypertrophy
and interstitial fibrosis in the presence of iPSC-MSCs might
restore cardiac function, similar to a rat model of post-ischemic
heart failure (Mias et al., 2009).
Despite unraveling some novel findings on the therapeutic
effect of iPSC-MSCs, several limitations pose the need for
further investigations in the future. Firstly, the current exposure
regimen of passive smoking for 8 weeks in animals may
not reflect the human scenario in active smokers. Secondly,
we did not fully explore the mechanistic insight how MSCs
exert their actions on lipid metabolism and the anti-oxidative,
anti-inflammatory, anti-hypertrophic and anti-fibrotic effects,
except the involvement of NF-κB signaling pathway. In addition,
due to the detection of small number of MSCs present in
the cardiac tissue (Supplementary Figure S2) after treatment,
paracrine effect might be the possible mechanism of MSCs
in the amelioration of CS-induced cardiac injury. In our
previous study, we found that the secretions from iPSC-MSCs
contained higher levels of macrophage migration inhibitory
factor (MIF), growth differentiation factor-15 (GDF-15) and stem
cell factor (SCF) than those from BM-MSCs, which might be
responsible for some of the anti-oxidative, anti-inflammatory
and anti-apoptotic effects of iPSC-MSCs (Zhang et al., 2015;
Li et al., 2017). Nevertheless, iPSC-MSCs treatment capable of
reducing CS-mediated cardiac dysfunction may be relevant to
human health. This study highlighted changes in lipid profile that
could potentially affect cardiac function. However, further studies
are warranted to provide more comprehensive information by
exploring specific pathways relevant to these changes in the rat
model of passive smoking.
CONCLUSION
Taken together, this study demonstrated a higher capacity of
iPSC-MSCs over BM-MSCs in improving the CS-induced cardiac
remodeling and dysfunction through the possible mechanisms
of the restoration of cardiac lipid abnormality as well as
the attenuation of cardiac oxidative stress, inflammation via
inhibition of NF-κB activation (Figure 6). These findings
indicate that iPSC-MSCs may be a promising candidate in cell-
based therapy to prevent cardiac complications in smokers.
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